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We report a case of human herpesvirus 6 (HHV-6)
encephalomyelitis in an immunocompetent patient, which
was confirmed by viral amplification from cerebrospinal
fluid. Cidofovir was used, followed by ganciclovir, because
of an adverse effect to probenecid. The patient recovered.
HHV-6 should be recognized as one of the causes of
encephalomyelitis.
H
uman herpesvirus 6 (HHV-6) is a member of the
Herpesviridae family. Like other members of this
family, the virus remains in a latent state after primary
infection has resolved and can reactivate. HHV-6
encephalomyelitis is an uncommon clinical manifestation
in immuncompetent adults. We report the case of a 20-
year-old immunocompetent woman who was hospitalized
with HHV-6 encephalomyelitis and recovered.
Case Report
A 20-year-old woman, with no history of medical prob-
lems, was admitted to the hospital on February 4, 2002,
with a 3-week history of asthenia, myalgia, low-grade fever,
urinary retention, and blurred vision. Physical examination
showed weakness of all extremities, paresis of her lower
limbs, and generalized hyperreflexia. Ocular examination
showed a bilateral papillitis and an optic neuritis. The
patient was given acyclovir (10 mg/kg, 3x/day) for clinical
encephalitis. Despite this treatment, her paresis increased
while in the hospital; she was bedridden and unable to sit
unsupported. Findings on cranial computed tomographic
scan were reported to be normal. Magnetic resonance imag-
ing (MRI) showed a focal lesion in the left thalamus, a
medullar cord enlargement, and multiple lesions in the
spinal cord white matter. These findings were consistent
with inflammatory myelitis but not with multiple sclerosis.
The patient did not exhibit any immune abnormalities.
After admission, her first cerebrospinal fluid (CSF)
sample was clear with an elevated opening pressure. Its
routine analysis indicated 178 leukocytes/mm3, with 90%
lymphocytes. Total protein and glucose levels were 0.77
g/L and 1.8 mmol/L, respectively. All CSF cultures were
negative for bacterial and fungal organisms. The sample
was positive for HHV-6 viral DNA by polymerase chain
reaction (PCR) (1) by using the primers H6.6 (5′-
AAGCTTGCACAATGCCAAAAAACAG-3′) and H6.7
(5′-CTCGAGTATGCCGAGACCCCTAATC-3′) amplify-
ing a 223-bp target sequence localized on the open reading
frame 13 of HHV-6 and followed by hybridization with the
5R probe (5′-CCGTCTTACTGTATCCGAAACAACT-
GTCTG-3′), whereas searching for other herpesviruses
(i.e, herpes simplex virus type 1 and 2, cytomegalovirus,
Epstein-Barr virus, and varicella-zoster virus) and
enteroviruses by PCR remained negative. HHV-6 was
shown to be A type by a previously described typing
method (2).
Because the patient was deteriorating rapidly, she was
given a high dose of intravenous methylprednisolone for 5
days. This treatment was not potent. When the diagnosis of
HHV-6 encephalomyelitis was established, methylpred-
nisolone was stopped and cidofovir (5 mg/kg for 1 day)
therapy was administered. The patient began to recover,
and 6 days after this therapy, results of CSF analysis
showed 115 leukocytes/mm3, with 95% lymphocytes, a
protein level of 0.6 g/L, and negative results of HHV-6
amplification. The patient experienced an adverse skin
reaction to probenecid given with cidofovir, and the treat-
ment was stopped. On February 27, the patient was still
exhibiting neurologic abnormalities, and her CSF was
once again positive for HHV-6 by PCR. Intravenous gan-
ciclovir (5 mg/kg twice daily) was then prescribed for 15
days. Within 1 month, the patient had recovered complete-
ly, with no sequelae or abnormalities on MRI. One year
after the episode of encephalomyelitis, the patient
remained free of neurologic defects (Figure). 
Several serum samples were taken from the patient on
days 2, 12, 22, and 66 after her admission. Serologic tests
showed for each serum the same result: anti-HHV-6
immunoglobulin (Ig) G titer of 160 by immunofluores-
cence assay, accompanied by anti-HHV-6 IgM, except on
day 66, showing that the virus had returned to its latent
state. The avidity index, measured according to the proce-
dure described by Ward et al. (3), was near 100% in the
first three serum samples, suggesting that this episode was
a reactivation of an existing viral infection. Serologic tests
for HIV were repeatedly negative, as were tests for herpes
simplex virus, Epstein-Barr virus (EBV), and
cytomegalovirus. HHV-6 PCR performed on peripheral
blood mononuclear cells was positive, although it was neg-
ative in the serum samples.
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1 month after discharge because of dysethesia of the lower
limbs, tonsillitis, asthenia, and low-grade fever. We
assumed it could be a novel reactivation of the HHV-6
infection, but this was not confirmed. It was, in fact, an
EBV primary infection. One month later, neurologic man-
ifestations had totally disappeared.
Conclusions
Humans are widely exposed to HHV-6 during child-
hood, and the seroprevalence is up to 100% in adults. Two
types of HHV-6 (A and B) can be identified; no diseases
have clearly been linked to HHV-6A infection, whereas
HHV-6B is responsible for the childhood disease exan-
them subitum. Exanthem subitum complications, includ-
ing seizures, hemiplegia, meningoencephalitis, or residual
encephalopathy, illustrate HHV-6 neurotropism; HHV-6
commonly invades the brain during ES, even in cases of
clinically asymptomatic infections. The virus then persists
in brain tissues in a latent form (4).
This case is, to our knowledge, the second of
encephalomyelitis caused by HHV-6 in an immunocompe-
tent patient. HHV-6 is frequently reported to be implicated
in encephalitis or meningoencephalitis in immunocompro-
mised persons, such as HIV-positive patients or transplant
recipients, but few reports have implicated HHV-6 in
encephalitis in immunocompetent adults (5–7). Our patient
was not immunocompromised by either drug therapy or
disease. Serologic tests suggested HHV-6 viral reactiva-
tion: IgG were present even in the first serum samples, and
the avidity index was high. Tests for IgM were positive as
well, but anti-HHV-6 IgM can be found during a viral reac-
tivation (8). Symptoms observed were likely to result from
a reactivated latent infection of virus in the brain. HHV-6
is known to reactivate frequently during acute infections
with other viruses especially with other herpesviruses (9).
Although our patient had neither obvious immunosuppres-
sion nor any confirmed infection, she may have had a
selective defect in her responses to HHV-6. The virus can
invade the central nervous system and, in some cases,
cause acute or subacute encephalitis sometimes associated
with diffuse or multifocal demyelinization (9).
In other cases of neurologic disease induced by HHV-6,
such as encephalomyelitis (10), meningoencephalitis (5,6),
or encephalitis (7) in immunocompetent adults, patients
were treated with acyclovir. Three patients died (6,7,9),
and one recovered within 2 days, with small doses of acy-
clovir (5). Data obtained in vitro indicate a greater suscep-
tibility of HHV-6 to cidofovir than ganciclovir or acyclovir
(11,12); acyclovir inhibited viral replication only at high
concentrations, so our patient was given cidofovir. This
regimen had clinical and virologic efficacy, as the patient
started to recover and her CSF improved. Viral DNA was
not detectable by PCR 6 days after the first injection of
cidofovir. Nevertheless, the patient needed other injections
of cidofovir to definitively cure the infection, as shown by
HHV-6 DNA in her CSF 16 days after the first injection.
The second injection was not possible because of a skin
reaction to probenecid. The second treatment given to the
patient was ganciclovir, which is known to be effective
against HHV-6. On this regimen, the patient completely
recovered from HHV-6 encephalomyelitis. Because this is
a case report and not a controlled clinical trial, we cannot
be certain that the antiviral drugs led to her recovery. We
note, however, that after cidofovir therapy was stopped,
HHV-6 DNA was again detected in the CSF, concurrent
with an increase in neurologic symptoms. She began to
recover after starting ganciclovir therapy. As a result, we
think that the antiherpesvirus drugs led to her recovery.
Of interest is the EBV primary infection that occurred
in this patient 1 month after discharge. The immunosup-
pression induced by HHV-6 probably favored the EBV
infection. The paresis observed during this episode was
considered a reactivation of the episode during her HHV-6
infection, since paresis is not a classical manifestation
accompanying EBV infection, 
DISPATCHES
730 Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 10, No. 4, April 2004
Figure. Clinical and therapeutic course and cerebrospinal fluid analysis. Dosage of acyclovir was 10 mg/kg, 3x/day, methylprednisolone
was 1 g/day, cidofovir was 5 mg/kg 1 day, ganciclovir was 5 mg/kg, 2x/day.In conclusion, the case reported here underlines the fact
that HHV-6 may cause rapidly multifocal, demyelinating
lesions in an immunocompetent adult, even in the case of
viral reactivation. Therefore, we think that HHV-6 should
be considered in the differential diagnosis of acute
demyelinating encephalomyelitis in immunocompetent
adults.
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References
1. Desachy A, Ranger-Rogez S, François B, Venot C, Traccard I,
Gastinne H, et al. Reactivation of human herpesvirus type-6 in mul-
tiple organ failure syndrome. Clin Infect Dis 2001;32:197–203.
2. Collot S, Petit B, Bordessoule D, Alain S, Touati M, Denis F, et al.
Real-time PCR for quantification of HHV-6 DNAin lymph nodes and
saliva. J Clin Microbiol 2002;40:2445–51.
3. Ward KN, Gray JJ, Joslin ME, Sheldon MJ. Avidity of IgG antibod-
ies to human herpesvirus-6 distinguishes primary from recurrent
infection in organ transplant recipients and excludes cross-reactivity
with other herpesviruses. J Med Virol 1993;39:44–9.
4. Luppi M, Barozzi P, Maiorana A, Marasca R, Torelli G. Human her-
pesvirus 6 infection in normal brain tissue. J Infect Dis
1994;169:943–4.
5. Torre D, Speranza F, Martegani R, Ferrante P, Omodeo-Zorini E,
Mancuso R, et al. Meningoencephalitis caused by human her-
pesvirus-6 in an immunocompetent adult patient: case report and
review of the literature. Infection 1998;26:402–4.
6. Beovic B, Pecaric-Meglic N, Marin J, Bedernjak J, Muzlovic I,
Cizman M. Fatal human herpesvirus 6 associated multifocal menin-
goencephalitis in an adult female patient. Scand J Infect Dis
2001;33:942–4.
7. Portolani M, Pecorari M, Tamassia MG, Gennari, W, Beretti F,
Guaraldi G. Case of fatal encephalitis by HHV-6 variant A. J Med
Virol 2001;65:133–7.
8. Suga S, Yoshikawa T, Asano Y, Nakashima T, Yazaki T, Fukuda M, et
al. IgM neutralizing antibody responses to human herpesvirus-6 in
patients with exanthem subitum or organ transplantation. Microbiol
Immunol 1992;36:495–506.
9. Braun DK, Dominguez G, Pellett PE. Human herpesvirus-6. Clin
Microbiol Rev 1997;10:521–67.
10. Novoa LJ, Nagra RM, Nakawatase T, Edwards-Lee T, Tourtelotte
WW, Cornford ME. Fulminant demyelinating encephalomyelitis
associated with productive HHV-6 infection in an immunocompetent
adult. J Med Virol 1997;52:301–8.
11. De Clercq E, Naesens L, De Bolle L, Schols D, Zhang Y, Neyts J.
Antiviral agents active against human herpesviruses HHV-6, HHV-7
and HHV-8. Rev Med Virol 2001;11:381–95.
12. Manichanh C, Grenot P, Gautheret-Dejean A, Debre P, Huraux JM,
Agut H. Susceptibility of human herpesvirus 6 to antiviral com-
pounds by flow cytometry analysis. Cytometry 2000;40:135–40.
Address for correspondence: E. Denes, Service des Maladies Infectieuses
et Tropicales, CHU Dupuytren, 2, Avenue Martin Luther King, 87042,
Limoges Cédex; fax : (33)-5-55-05-66-48; email: eric.denes@unilim.fr
Human Herpesvirus 6 Encephalomyelitis
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 10, No. 4, April 2004 731
The print journal is available at no charge to public health professionals
YES, I would like to receive Emerging Infectious Diseases.
Please print your name and business
address in the box and return by fax to
404-371-5449 or mail to
EID Editor
CDC/NCID/MS D61
1600 Clifton Road, NE
Atlanta, GA 30333
Moving? Please give us your new address (in the box) and print the number of your old
mailing label here_________________________________________
	



